Mild homocysteinemia occurs surprisingly often in patients with premature vascular disease. We studied the possible enzymatic sources of this mild hyperhomocysteinemia and the control of homocysteine levels in plasma by treatment of patients with the cofactors and cosubstrates of homocysteine catabolism. We assessed homocysteine metabolism in 131 patients who had premature disease in their coronary, peripheral, or cerebrovascular circulation by using a standard oral methionine-load test Impaired homocysteine metabolism occurred in 28 patients. We assayed levels of the primary enzymes of homocysteine catabolism in cultured skin fibroblast extracts from 15 of these 28 patients. The patients' cystathionine 0-synthase levels (3.68±2.52 nmol/h per milligram of cell protein, mean±SD) were markedly depressed compared with those from 31 healthy adult control subjects (7.61 ±4.49, P<.001). The patients' levels of 5 -methyltetrahydrofolate: homocysteine methyltransferase were normal. While betalne: homocysteine methyltransferase was not expressed in skin fibroblasts, 24-hour urinary betaine and fyiV-dimethylglycine measurements were consistent with normal or enhanced remethylation of homocysteine by betaine: homocysteine methyltransferase in the 13 patients tested. When treated daily with choline and betaine, pyridoxine, or folic acid, there was a normalization of the postmethionine plasma homocysteine level in 16 of 19 patients. Our results indicate that mild homocysteinemia in premature vascular disease may be caused by either a folate deficiency or deficiencies in cystathionine /3-synthase activity. It does not necessarily involve deficiencies of either 5-methyltetrahydrofolate: homocysteine methyltransferase or betaine: homocysteine methyltransferase. Effective treatment regimens are also defined. (Arteriosder Thromb. 1993;13:1253-1260 KEYWORDS • coronary heart disease • 5-methyltetrahydrofolate: homocysteine methyltransferase • cystathionine 0-synthase • betaine: homocysteine methyltransferase
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Mild homocysteinemia occurs surprisingly often in patients with premature vascular disease. We studied the possible enzymatic sources of this mild hyperhomocysteinemia and the control of homocysteine levels in plasma by treatment of patients with the cofactors and cosubstrates of homocysteine catabolism. We assessed homocysteine metabolism in 131 patients who had premature disease in their coronary, peripheral, or cerebrovascular circulation by using a standard oral methionine-load test Impaired homocysteine metabolism occurred in 28 patients. We assayed levels of the primary enzymes of homocysteine catabolism in cultured skin fibroblast extracts from 15 of these 28 patients. The patients' cystathionine 0-synthase levels (3.68±2.52 nmol/h per milligram of cell protein, mean±SD) were markedly depressed compared with those from 31 healthy adult control subjects (7.61 ±4.49, P<.001). The patients' levels of 5 -methyltetrahydrofolate: homocysteine methyltransferase were normal. While betalne: homocysteine methyltransferase was not expressed in skin fibroblasts, 24-hour urinary betaine and fyiV-dimethylglycine measurements were consistent with normal or enhanced remethylation of homocysteine by betaine: homocysteine methyltransferase in the 13 patients tested. When treated daily with choline and betaine, pyridoxine, or folic acid, there was a normalization of the postmethionine plasma homocysteine level in 16 of 19 patients. Our results indicate that mild homocysteinemia in premature vascular disease may be caused by either a folate deficiency or deficiencies in cystathionine /3-synthase activity. It does not necessarily involve deficiencies of either 5-methyltetrahydrofolate: homocysteine methyltransferase or betaine: homocysteine methyltransferase. Effective treatment regimens are also defined. (Arteriosder Thromb. 1993;13:1253-1260.) KEYWORDS • coronary heart disease • 5-methyltetrahydrofolate: homocysteine methyltransferase • cystathionine 0-synthase • betaine: homocysteine methyltransferase A lthough occlusive vascular events occur more fre-/ \ quently in patients who have one or more J.A.
recognized cardiovascular risk factors, in a significant number of patients none can be identified. In some patients the only obvious risk factor is a family history of premature cardiovascular disease; whether this is a genetic susceptibility and if so, which gene(s) is involved, are not known. In 1976, mild homocysteinemia, such as might arise from heterozygosity for cystathionine /3-synthase (EC 4.2.1.22; C/3S) deficiency, was suggested as a possible new cardiovascular risk factor. 1 Various studies have since tested this proposal, usually by measuring plasma homocyst(e)ine levels after an oral methionine-load test in patients with premature atherosclerosis or thrombosis at one of several sites in the vascular tree (listed in Reference 2). In addition, there have been two reports comparing C/3S activity in such patients with that in healthy control subjects. 34 These studies have found that in patients with cerebrovascular or peripheral vascular disease, there is a consistently much higher frequency (by a factor of perhaps 25-fold) of impaired homocysteine metabolism than in the general community. An early study suggested that an increased frequency of impaired homocysteine metabolism, as tested by oral methionine loading, did not occur in patients with premature coronary artery disease. 3 However, findings from other laboratories have subsequently reversed this claim.
2 -4 One recent study has also shown that hyperhomocyst(e)inemia associated with premature coronary heart disease is at least partly familial. 5 In the two studies of C/3S levels, patients with premature cerebrovascular or peripheral vascular disease and impaired homocysteine metabolism were generally found to possess low synthase activity, consistent with their being heterozygotes for C/3S deficiency. 34 The deficiency of C/3S in these patients might explain their impaired homocysteine metabolism. However, there has been no report of measurement in such patients of the other primary enzymes of homocysteine catabolism, betaine: homocysteine methyltransferase (EC 2.1.1.5; BHMT) and 5-methyltetrahydrofolate:homocysteine methyltransferase (EC 2.1.1.13; FHMT).
In the present study we tested the homocysteine metabolism of patients who had both premature vascular disease and impaired methionine tolerance by investigating possible deficiencies of the three primary enzymes of homocysteine catabolism. In addition to direct enzyme assays, this investigation involved a study of the response of these patients to brief treatments with those vitamins and cosubstrates that are known to stimulate each of the three major homocysteine catabolic pathways and a search for differential responses in different patients that might point to their enzyme defects. The treatments included vitamin B 6 , folic acid, and betaine and choline, which are involved in the Q3S, FHMT, and BHMT pathways, respectively.
Methods
Protocol
All 131 vascular disease patients enrolled in this study underwent an initial oral methionine-load test. If their plasma free homocyst(e)ine levels at both 4 and 8 hours after methionine ingestion were at least two standard deviations above the mean for their appropriate healthy control group at the same time point, they were then denned as having impaired homocysteine metabolism and were studied further.
Skin samples were cultured from 15 vascular disease patients who were found to have impaired homocysteine metabolism and 31 healthy control subjects. Cultured fibroblasts from these samples were assayed for C/3S and FHMT activity. Urine samples from 13 patients and 9 control subjects were used to assess their BHMT status.
Fifteen vascular disease patients with impaired homocysteine metabolism were treated in an attempt to lower their plasma homocyst(e)ine levels and were monitored by the methionine-load test. Finally, 12 such patients were treated with a combination of pyridoxine (100 mg daily) and folic acid (5 mg daily) for at least 3 months before a subsequent methionine-load test to reassess their plasma homocysteine levels.
Patients
Patients were enrolled for the initial methionine-load test if they had vascular disease in one of the following categories: (1) age ^52 years with angiographically confirmed coronary artery disease; (2) age <61 years with cerebrovascular disease; and (3) age <61 years with peripheral vascular disease. Patients were drawn from the Departments of Cardiovascular Medicine, Neurology, and Rehabilitation of the Prince Henry/ Prince of Wales Hospitals, Sydney, Australia, and were selected if they had few or no obvious risk factors, rather than on a sequential or random basis. Information gained from male patients and from premenopausal and postmenopausal female patients was segregated because plasma homocysteine levels in these three groups have been reported to differ. 6 Table 1 shows the distribution of patients among the categories. The average age (in years, mean±SD) of patients was as follows: for coronary artery disease, males 41.4±7.1 (n=48), and premenopausal females 44.0±5.0 (n=14); and for other vascular disease, males 43.6±12.5 (n=36), premenopausal females 36.5 ±13.9 (n=24), and postmenopausal females, 54.2±6.1 (n=9).
Patients enrolled in both the skin-sample enzyme study and the cofactor treatment investigation were generally those vascular disease patients who were identified early in the screening program as having impaired homocysteine metabolism. Thirteen of the patients in the skin-sample study were also tested by cofactor treatment and are identified in The numbers of patients in each category who were found to have impaired homocysteine metabolism by this test are given in parentheses.
"We encountered no postmenopausal women aged s52 years with coronary artery disease while recruiting for this study.
tincludes four patients with venous thromboses.
Liver and renal functions were found to be normal in all patients. Serum B 12 and folate levels were measured in 126 patients as well as erythrocyte folate levels in 60 of these patients. Standard methods were used by the Department of Clinical Chemistry to assess liver and renal functions, and folate and vitamin B 12 levels were assayed by the Department of Haematology, the Prince Henry/Prince of Wales Hospitals.
Heterozygotes for CfiS Deficiency
A total of 21 parents of homocystinuria patients in our care were tested with an oral methionine load. All of these patients had typical clinical and biochemical features of homozygous C/3S deficiency, and their parents were presumed to be C/3S heterozygotes. Among the heterozygotes were 10 males, 9 premenopausal females, and 2 postmenopausal females, aged 49.1 ±14.4, 42.9±7.8, and 57 and 67 years, respectively. Ten families were represented by both parents.
Control Subjects
Healthy adult control subjects for each step of the protocol were obtained either through contacts with our laboratory staff or by advertising within the Prince Henry/Prince of Wales Hospitals and the University of New South Wales. These subjects had no evidence of present or previous vascular disease at the time of testing. Of a total of 56 control subjects who underwent an oral methionine-load test, there were 20 males with a mean age ±SD of 34.6 ±14.5 years and 25 premenopausal and 11 postmenopausal females, aged 28.8 ±8.1 and 59.1 ±8.3 years, respectively.
Although these control subjects were gathered from age ranges comparable with those of the patient and heterozygous groups, the differences in age ranges between patients with coronary artery disease and other patients and between patients and heterozygotes meant that the control group was not precisely age matched with any other specific patient or heterozygous group. Liver and renal functions were normal in all control subjects, and 52 of these control subjects had serum B 12 and folate levels assessed. Thirty-one control subjects provided skin samples for assays of Q3S and FHMT activities in cultured skin fibroblasts. There were 16 males (mean±SD age, 44.1 ±11.2 years) and 15 females (43.4±10.4 years). There was at least one control subject of the same sex and of very similar age to each patient with premature vascular disease whose skin fibroblast enzymes were assayed. Q3S, cystathionine 0-synthase; FHMT, 5 -methyltetrahydrofolate: homocysteine methyltransferase; CV, cerebrovascular; Cor, coronary artery; PV, peripheral vascular.
'The 4-and 8-hour postmethionine plasma homocyst(e)ine levels were averaged, and the ratios between the mean value after a particular treatment, compared with the mean value from the initial methionine load response, are given. tThe 4-hour postmethionine plasma homocyst(e)ine level after folic acid/pyridoxine was compared with the corresponding plasma homocyst(e)ine level from the initial methionine-load test.
tEnzyme activity is in nanomoles per hour per milligram of cell protein.
§Normal values are presented as mean and (SD); for C/3S and FHMT assays in normal control subjects, n=31 and 30, respectively.
Oral Methionine-Load Test
Initial methionine-load tests of patients and all methionine-load tests of control subjects and heterozygotes were carried out after the subjects had abstained from taking any vitamin preparations for at least 6 weeks. After a 10-hour overnight fast, a 10-mL venous blood sample was drawn and then each patient was given an oral methionine load of 4 g/m 2 of body surface area (=0.1 g/kg of body weight) in orange juice. Additional venous blood samples were drawn 4 and 8 hours later. After the 4-hour sample each patient ate a standard chicken sandwich lunch. The plasma free homocyst(e)ine level (defined as the concentration of homocysteine-cysteine mixed disulfide plus twice the concentration of homocystine) in the venous blood samples was monitored as described 7 by using either a JEOL JLC-6AH or a Beckman 6300 amino acid analyzer with standard lithium citrate buffers.
We compared the absolute level of plasma homocysteine after an oral methionine load against the level of increase in plasma homocyst(e)ine above the fasting (baseline) level caused by the methionine load after both 4 and 8 hours in heterozygotes for C/3S deficiency and control subjects. We calculated the mean+2 SD for these four parameters in our 56 normal control subjects and looked for values above these limits in the 25 methionine-load tests obtained for 21 heterozygotes for C/3S deficiency who were not receiving therapy.
The absolute values of 4-and 8-hour plasma homocyst(e)ine concentrations were clearly more sensitive detectors of heterozygotes, identifying 12 of 21, than were the differences between baseline and the 4-and 8-hour values, which identified only 7 of these 12; no additional elevated results were identified. Repeated methionine-load tests of 4 heterozygotes confirmed the initial test classifications. Thus, patients are defined as having impaired homocysteine metabolism only if both their 4-and 8-hour postmethionine plasma homocyst(e)ine levels were higher than the appropriate normal mean+2 SD.
Treatment of the patients who received combined pyridoxine/folic acid therapy was monitored with an abbreviated methionine-load test. In this load test, plasma homocyst(e)ine was measured at 0 and 4 hours only after methionine ingestion.
Assays of CfiS and FHMT Activity
A single sample of skin was obtained from the inner forearm of each subject after local anaesthesia and via a 3-mm skin biopsy punch. Skin samples were cultured for 6 weeks in Ham's F-10 medium supplemented with 10% fetal calf serum and finally in roller bottles for 6 to 8 days, during which time they became fully confluent. Cells were then washed twice with Dulbecco's phosphate-buffered saline (2.7 mmol/L KC1, 1.5 mmol/L KH 2 PO 4 ,137 mmol/L NaCl, and 8.1 mmol/L Na 2 HPO 4 ; pH 7.4), trypsinized, washed twice more with the same buffered saline, centrifuged, drained, sealed, and stored at -70°C for 0.6 to 6.8 months before assay.
For the assays these stored cells were thawed, resuspended in 50 mmol/L sodium phosphate buffer, pH 7.4, sonicated, and centrifuged. The supernatant was used as the enzyme source. Protein concentrations were measured by the procedure of Lowry et al. 8 Q3S was assayed by amino acid analysis of formed cystathionine, as recently reported. 9 This assay quantifies a clearly delineated peak of cystathionine, has already been validated, and is unaffected by a pyridoxine complex that interfered with a previously employed amino acid analysis-based assay.
10 C/3S activity for the different control subjects was not related to the period of the final subculture. Furthermore, there was no correlation between C/3S activity and the period of storage of cells at -70°C (0.6 to 6.8 months) between harvesting and assay.
Cell extracts were assayed in duplicate in batches of 10 or 15, with each batch containing 1 or 2 healthy control cell supernatants for each cell supernatant from a patient who was matched by age and sex with the 1 or 2 control subjects. Each batch of C0S assays included duplicate standard samples (aliquots of a single batch of chicken liver supernatant that had been stored at -70°C for the duration of the assays, which was less than 2 months). Values of C/3S activity that were determined for fibroblast supernatants in these assays were then normalized to the values obtained for the chicken liver supernatant standards in that assay.
The FHMT activity in cell extracts was determined by the formation in the dark of [ u C]methionine from [methyl-14 C]5-methyltetrahydrofolate and homocysteine as described.
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Urinary Betaine and N,N-Dimethylgfycine Determinations for Assessment of BHMT Status
Aliquots (10 mL) of 24-hour urine samples were freeze-dried, the resulting solids were resuspended in 2.0 mL deuterium oxide and centrifuged, and the supernatant was analyzed by proton nuclear magnetic resonance (NMR). Spectra were obtained using 2,2-dimethyl-2-silapentane-5-sulfonate as the internal standard on a Bruker AMX 400wb NMR spectrometer as detailed elsewhere (P.
12 These identifications were confirmed by NMR spectroscopy of a 24-hour urine specimen from a healthy adult male who had consumed betaine, 3 g twice daily, for 7 days before collection of urine.
Betaine and N,7V-dimethylglycine concentrations were quantified by integrating areas of known peaks from these two compounds. Betaine peaks were treated by standard exponential line broadening. Peaks of N,Ndimethylglycine were treated by sine-window apodization of the data to minimize the interfering effects of other adjacent peaks. In two samples this interference precluded an estimation of the 7V,./V-dimethylglycine concentration. The detection limit with respect to these two samples was approximately 15 /xmoI/L.
Cofactor and Cosubstrate Follow-up Studies
Treatment of patients to lower their plasma homocyst(e)ine levels involved serial oral therapy with choline (1 g twice daily for 1 week), betaine (N,N,Ntrimethylglycine; 0.84 g twice daily for 1 week), pyridoxine (100 mg/d for 2 weeks), and folic acid (5 mg/d for 2 weeks). At the end of the treatment period with each cofactor or cosubstrate, a methionine-load test was performed; 3 weeks were allowed between this methionine-load test and the start of the next treatment. Two coronary artery patients reported nausea after choline therapy, and the choline treatment was stopped immediately.
Statistical comparisons were generally carried out using Student's t test. However, the Mann-Whitney rank test was used to evaluate urinary metabolite results, as the betaine data were discontinuously distributed. All subjects involved in this study gave their informed consent, and the project was approved by the Ethics Committee of the University of New South Wales.
Results
Of the 131 patients who underwent the initial methionine-load test, 28 (21.4%) had impaired homocysteine metabolism. Their distribution among vascular disease and gender categories is given in Table 1 . Of note is the proportion (13/62, or 21%) of patients with coronary artery disease who had impaired homocysteine metabolism. This was not different from the proportion in the whole group. By contrast, none of the 56 healthy normal control subjects had impaired homocysteine metabolism as defined. Figure 1 shows the 4-hour postmethionine plasma homocyst(e)ine levels of all patients, heterozygotes, and normal control subjects. The homocyst(e)ine levels of the patients who were categorized as having impaired homocysteine metabolism occurred within approximately the same range as the upper levels recorded for C/3S heterozygotes. There were 2 control subjects and 6 patients (FF, HH, OO, RR, TT, VV, and ZZ) who had serum folate levels below the normal range. Of all subjects tested, only 1 of the 2 affected control subjects and 1 other patient (BB) had subnormal red cell folate levels. All patients with depressed serum or red cell folate levels had impaired homocysteine metabolism as defined by the methionineload test. One control subject and 2 patients (FF and AA) had depressed serum vitamin B 12 levels.
Enzyme Studies
We studied the enzymes directly involved in homocysteine catabolism to investigate the mechanisms of impaired homocysteine metabolism in these patients with premature vascular disease. The Q3S activities of patients (Table 2 ) and control subjects varied over wide ranges and had a substantial overlap, although the patients' levels were generally lower than control levels (Fig 2) . There was no significant correlation between Q3S activity and the age of either the patients or the control subjects for the age range studied in both groups. The mean value (±SD) for patients of 3.68±2.52 nmol/h per milligram of cell protein was almost exactly half the control value of 7.61 ±4.49 nmol/h per milligram of cell protein (P<.001).
By contrast, FHMT activities for these same two groups varied over much narrower ranges (Table 2) , and the mean±SD for patients (11.15±2.04 nmol/h per milligram of cell protein) was not significantly different from that of control subjects (11.70±1.64 nmol/h per milligram of cell protein). The correlation between FHMT activity and age (Fig 3) for patients, r=-0.51, was essentially significant (P=.O5O1), while that for control subjects was not.
The third enzyme directly involved in homocysteine catabolism, BHMT, is not measurable in either cultured skin fibroblasts or peripheral blood lymphocytes. 13 We postulated that a BHMT deficiency would result in increases in both plasma homocyst(e)ine and betaine 
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and that the excess betaine would be excreted in the urine. On the basis of previous observation, 12 we further hypothesized that persons deficient in BHMT activity could be expected to excrete lower than nonnal levels of urinary JV,Af-dimethylglycine.
Analyses of 24-hour urine samples from 13 patients from the same group whose fibroblast C/3S and FHMT activities were determined and from 9 normal control subjects were performed by NMR. This showed that the urinary betaine levels of all but three patients (II, KK, and NN) were within 1 SD of the normal mean (Table  3 ). These three patients had urinary 24-hour betaine levels elevated above the normal mean+2 SD, as did one nonnal control subject. Patients' and control subjects' results were not significantly different.
However, the urinary A^N-dimethylgh/cine levels in patients were higher than those of control subjects (P=.01). In particular, the A^N-dimethylglycine levels of the 3 patients who had elevated urinary betaine levels were well above the normal mean, thus arguing against a functional deficiency of BHMT in these patients. By contrast, the control subject with elevated urinary betaine levels had a depressed JV,./V-dimethylglycine level, suggestive of deficient BHMT activity.
Vitamin and Cosubstrate Therapy
We explored the responses of patients to various treatments to enhance homocysteine catabolism, in the hope that different effects of these potential promoters of homocysteine catabolism would provide further information on the nature of the suspected enzyme defect. Table 2 presents the results of this cofactor screening study. Because of changes of residence for several patients and because several others declined to complete the test series, the results shown in Table 2 are not comprehensive. Nevertheless, several trends emerged. First, there are two patients (CC and FF) for whom therapy with each of the vitamins and methyl donors achieved little or no effect. Another patient (AA) responded well to pyridoxine only. In the remaining 8 patients who underwent all or a substantial proportion of the full treatment program, the biochemical response was similar for each treatment. Second, after choline treatment the decrease in the postmethionine plasma homocyst(e)ine level in all patients tested (except GG) was quantitatively very similar to that achieved with betaine, as would be expected if betaine were derived solely from choline in vivo.
When patients underwent longer-term treatment with pyridoxine and folic acid, we found that their mean postmethionine plasma homocyst(e)ine level (±SD) after treatment was 49±15% of the corresponding initial methionine-load test value (P=.0001). Of these patients, 5 had also been treated with pyridoxine alone, after which time their postmethionine plasma homocyst(e)ine levels were 65±13% of their initial pretreatment values (/ > =.O15). Similarly, 6 had been treated with folic acid alone, leading to postmethionine homocyst(e)ine levels of 55±14% of their untreated values (P=.0011). Treatment with pyridoxine or folic acid alone gave results that were not significantly different from treatment with pyridoxine and folic acid together. There was no statistical difference between treatment with pyridoxine or folic acid alone. With one exception, restoration of postmethionine plasma homocyst(e)ine levels of these patients to normal or near-normal levels coincided with their therapy with combined pyridoxine and folic acid.
Discussion
In this study we examined 131 patients with premature vascular disease at various sites in the vascular tree by an oral methionine-load test. When applied to a group of obligate heterozygotes for C/3S deficiency, this test detected 57% of the heterozygotes and none of the 56 healthy control subjects as having an abnormal homocysteine metabolism. As the methionine-load test substantially underestimated the numbers of heterozygotes, the proportion of patients who are heterozygotes could be significantly higher than indicated by the screening procedure.
In each vascular disease category we found substantially more patients whose plasma homocyst(e)ine levels were elevated after oral methionine ingestion than would have been expected from the known incidence of heterozygosity for Q3S deficiency in New South Wales, which is =1%. 1 4 This study has produced strong evidence that in patients with premature coronary artery disease in our community, impaired homocysteine metabolism occurred at a frequency similar to that which we and others have found in patients with precocious peripheral and cerebrovascular disease. Our findings in the coronary artery patients contrast with results for a similar group of patients reported by Boers et al, 3 while being numerically similar to results reported by Murphy-Chutorian et al. 15 We noted the high proportion (4/9) of postmenopausal vascular disease patients who were found to have impaired homocysteine metabolism, although their numbers are too small to be conclusive.
In investigating possible reasons for impaired homocysteine metabolism in patients with premature occlusive vascular disease, there were at least two patients, RR and TT, whose levels of C/3S and FHMT were normal and whose only relevant abnormality appeared to be their depressed serum folate levels. Previous work has indicated that a depressed serum folate level alone may cause homocysteinemia. 16 Of the other patients with depressed folate levels, 3 (BB, HH, and VV) had low levels of Q3S activity as well, and 3 were not tested for enzyme activities. Folate deficiency has previously been noted in patients who have homocysteinemia due to a deficiency of QJS activity, 1718 suggesting that this may have happened in patients BB, HH, and VV.
In the 15 patients whose skin fibroblasts were assayed, there was no evidence to implicate a deficiency of FHMT as the cause of their condition. On the other hand, levels of C^S activity in these patients were, for the most part, substantially below the appropriate mean values of normal control subjects. This finding, which agrees with two earlier reports that found that impaired homocysteine metabolism in patients with premature vascular disease is associated with diminished C/3S activity in most of them, 34 broadens the earlier findings as follows. First, a different Q3S assay has been used here, with a more precise delineation of the cystathionine peak than in alternative methods. Second, the fact that the specific activity of FHMT for the patients is essentially the same as that of control subjects while the specific activity of C/3S is substantially lower indicates that the Q3S result for the patients is not simply an artifact of fibroblast growth rate or extraction.
Because the C/3S activity of most patients' fibroblasts is low after many generations in culture, suggesting a heritable deficiency, and because hyperhomocysteinemia associated with vascular disease has a substantial familial component, 5 it seems reasonable to link these two observations. Whether the C/3S deficiency is caused by a mutation in at least one allele of the C/3S structural gene, as inferred previously, 34 or by an alteration in the system that regulates expression of the C/3S protein is not known. The substantial scatter of normal values for this enzyme noted both here and elsewhere 19 means that it is not possible to unambiguously ascribe individual values to Q3S heterozygotes. 19 This point is highlighted by our finding of near-zero C/3S activities in 1 control subject and 2 patients, despite their substantial FHMT activity. We do not have a clear explanation for these low C/3S levels. However, the fact that the mean C/3S activity of all patients assessed was almost exactly 50% of the normal mean strongly suggests that at least some patients are heterozygotes. Additional support comes from our finding (Fig 1) that the upper levels of postmethionine plasma homocyst(e)ine in our patients occur in very much the same range of values as the higher postmethionine plasma homocyst(e)ine levels from obligate heterozygotes; previous reports also showed this trend. 20 However, the report that C/3S activity in cultured human cells tends to decline with age 21 suggests that caution should be used in interpreting the C/3S activity levels of our patients, although our observations here do not support the notion of a decline in Q3S activity with age over the age range studied (25 to 60 years; Fig 2) . These considerations indicate that suspected heterozygosity for C/3S deficiency would best be explored by gene technology, for example, by looking for irregularities in C/3S message cDNA using appropriate probes, and we are currently investigating this possibility.
The urinary betaine and TV, ./V-dimethylglycine measurements when taken together do not indicate a deficiency of BHMT activity in any particular patient. This finding is important, because it suggests that in our patients who had impaired homocysteine metabolism and who had their enzyme and urinary metabolites measured, the only evidence of enzyme deficiency was in C/3S, since their FHMT levels were normal.
Our observation that some urinary betaine and more A^Af-dimethylglycine levels in patients appeared elevated compared with control levels is noteworthy and deserves further investigation. Elevated urinary N,Ndimethylglycine levels would be consistent with an increased rate of homocysteine-dependent demethylation of betaine in these patients. The finding that patients who have elevated A^Af-dimethylglycine levels also have either normal or raised urinary betaine levels could indicate that these patients also have accelerated rates of betaine biosynthesis. The possibility that urinary betaine and Af,Af-dimethylglycine levels are linked in these patients, as required by the above hypothesis, is supported by the correlation between the levels (r=0.47, n=ll,P=.14).
It is clear that methionine-load test results comment on the homocysteine catabolism of patients under special metabolic stress. However, levels of betaine and N,N-dimethylglycine in either urine or plasma collected under nonloading conditions as reported here may more directly reflect the usual daily activity of BHMT and the rate of remethylation of homocysteine by BHMT in the subjects. In this respect it is noteworthy that patient NN, who had the highest urinary betaine and high N,Ndimethylglycine levels, was the only one of 13 patients who when treated with combined pyridoxine and folic acid still had a substantially elevated postmethionine plasma homocyst(e)ine (see Table 2 ). This may be related to his low fibroblast QJS activity (1.49 nmol/h per milligram of protein). The other two patients with high levels of urinary betaine and /y,7V-dimethylglycine also had depressed QJS activity (patient II, 3.70 and patient KK, 0.56 nmol/h per milligram of protein).
The vitamin /cosubstrate study of patients revealed at least two different types of response. In 8 patients, each treatment with choline, betaine, pyridoxine, or folic acid led to proportionately similar decreases in the levels of postmethionine plasma homocyst(e)ine compared with those in the initial methionine-load test. In 2 other patients, CC and FF, there was no significant decrease in homocyst(e)ine after treatment, and in a third patient, AA, an intermediate type of response was observed. The first type of response was characteristic of patients who had normal FHMT and decreased Q3S activities. Unfortunately, we were unable to obtain skin samples from the 2 patients who gave the second type of response to vitamin/cosubstrate treatment or from patient AA to look for different patterns of FHMT and C/3S activities.
The results obtained in this study suggest that the majority of patients who have premature vascular disease and impaired homocysteine metabolism have normal levels of FHMT and probably also BHMT activity. Their levels of C/3S are low. Our studies with obligate heterozygotes showed that while approximately half had significantly elevated plasma homocyst(e)ine levels after an oral methionine-load test, the remaining heterozygotes had normal levels. This indicates that heterozygosity for C£S deficiency is not by itself sufficient to account for impaired homocysteine metabolism as measured by the methionine-load test. Either a particular type of C0S mutation is involved or other factors limit the rate of homocysteine catabolism. One possibility that we are currently exploring is that variants of 5,10-methylenetetrahydrofolate reductase, 22 which occur frequently in the general community, could be present and further compromise the catabolism of homocysteine.
